Promising combo trial halted early – too few patients to draw conclusions
NCT ID NCT05317936
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This small early-phase trial tested whether adding pirtobrutinib to venetoclax could wipe out leftover cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 people enrolled before the study was terminated, so we cannot draw any reliable conclusions about safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib and venetoclax
What this could lead to
If it works, this combination could help people with CLL/SLL achieve deeper remission by wiping out leftover cancer cells after standard treatment.
What could go wrong
The trial was terminated early with only 3 participants, so we have very little data. It is too early to know if the combination is safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.